Kite, a Gilead Company, announced on July 24, 2020 that FDA granted accelerated approval to Tecartus (brexucabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
According to a comp
